# Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL

> **NCT02399085** · PHASE2 · COMPLETED · sponsor: **MorphoSys AG** · enrollment: 81 (actual)

## Conditions studied

- Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** Tafasitamab
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT02399085
- **Lead sponsor:** MorphoSys AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-29
- **Primary completion:** 2022-11-14
- **Final completion:** 2023-04-19
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2023-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02399085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02399085, "Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02399085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*